Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.

Wijeratne A, Xiao J, Reutter C, Furness KW, Leon R, Zia-Ebrahimi M, Cavitt RN, Strelow JM, Van Horn RD, Peng SB, Barda DA, Engler TA, Chalmers MJ.

ACS Med Chem Lett. 2018 May 21;9(6):557-562. doi: 10.1021/acsmedchemlett.8b00110. eCollection 2018 Jun 14.

2.

A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.

Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K, Peng SB, McCann DJ.

Mol Cancer Ther. 2011 Nov;10(11):2200-10. doi: 10.1158/1535-7163.MCT-11-0306. Epub 2011 Sep 7.

3.

The first total synthesis of lipid II: the final monomeric intermediate in bacterial cell wall biosynthesis.

VanNieuwenhze MS, Mauldin SC, Zia-Ebrahimi M, Winger BE, Hornback WJ, Saha SL, Aikins JA, Blaszczak LC.

J Am Chem Soc. 2002 Apr 10;124(14):3656-60.

PMID:
11929255
4.

The total synthesis of lipid I.

VanNieuwenhze MS, Mauldin SC, Zia-Ebrahimi M, Aikins JA, Blaszczak LC.

J Am Chem Soc. 2001 Jul 25;123(29):6983-8.

PMID:
11459476

Supplemental Content

Loading ...
Support Center